These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38750400)

  • 21. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishing a protocol for the compatibilities of closed-system transfer devices with multiple chemotherapy drugs under simulated clinical conditions.
    Chiang SC; Shen M; Lin CC; Chang HP
    PLoS One; 2021; 16(9):e0257873. PubMed ID: 34582474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of Contamination with Antibiotics on Surfaces and in Environmental Air in Three European Hospitals Following Implementation of a Closed-System Drug Transfer Device.
    Sessink PJM; Nyulasi T; Haraldsson ELM; Rebic B
    Ann Work Expo Health; 2019 Apr; 63(4):459-467. PubMed ID: 30852616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Container closure integrity testing and process validation of closed system transfer devices for aseptic reconstitution of drug vials connected to fluid bags.
    van den Berg RB; Akgöl K; Swart EL; Nuijen B; Crul M
    Eur J Hosp Pharm; 2024 Jun; 31(4):358-362. PubMed ID: 36792349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of three barrier-type closed system transfer devices using the 2015 NIOSH vapor containment performance draft protocol.
    Szkiladz A; Hegner S
    Drugs Ther Perspect; 2022; 38(4):177-184. PubMed ID: 35313703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a simple compatibility inspection method using pressure in a BD PhaSeal™ system and hazardous drug vials.
    Ishimaru H; Tsuda Y; Kage H; Kawano T; Takayama S; Morimoto Y; Goto K; Watanabe K
    J Oncol Pharm Pract; 2021 Sep; 27(6):1321-1327. PubMed ID: 32854576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-drug conjugates- stability and formulation.
    Duerr C; Friess W
    Eur J Pharm Biopharm; 2019 Jun; 139():168-176. PubMed ID: 30940541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of the 2015 proposed NIOSH vapor containment performance protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs.
    Forshay CM; Streeter SO; Salch SA; Eckel SF
    J Oncol Pharm Pract; 2019 Jul; 25(5):1160-1166. PubMed ID: 30041583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Closed System Transfer Devices in Preventing Chemotherapy Agents Contamination During Compounding Process-A Single and Comparative Study in China.
    Tang Y; Che X; Wang YL; Ye X; Cao WL; Wang Y
    Front Public Health; 2022; 10():827835. PubMed ID: 35509509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
    Gikanga B; Chen Y; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
    Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
    Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of subvisible particle formation during the filling pump operation of a monoclonal antibody solution.
    Nayak A; Colandene J; Bradford V; Perkins M
    J Pharm Sci; 2011 Oct; 100(10):4198-204. PubMed ID: 21698601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device.
    Sessink PJ; Trahan J; Coyne JW
    Hosp Pharm; 2013 Mar; 48(3):204-12. PubMed ID: 24421463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding.
    Soefje S; Rickabaugh K; Rajkumar R; Wall KP
    Int J Pharm Compd; 2022; 26(1):72-79. PubMed ID: 35081047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding.
    Soefje S; Rickabaugh K; Rajkumar R; Wall KP
    Int J Pharm Compd; 2021; 25(6):515-522. PubMed ID: 34807847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance testing protocol for closed-system transfer devices used during pharmacy compounding and administration of hazardous drugs.
    Wilkinson AS; Allwood MC; Morris CP; Wallace A; Finnis R; Kaminska E; Stonkute D; Szramowska M; Miller J; Pengelly I; Hemingway M
    PLoS One; 2018; 13(10):e0205263. PubMed ID: 30379831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticancer drug waste minimization and cost-saving study by using a closed-system transfer device for chemotherapy compounding.
    Adade CA; Diop BB; Attjioui H; Cheikh A; Mefetah H; Bouatia M
    J Oncol Pharm Pract; 2022 Apr; 28(3):605-612. PubMed ID: 33847197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process.
    Valero S; López-Briz E; Vila N; Solana A; Melero M; Poveda JL
    Regul Toxicol Pharmacol; 2018 Jun; 95():1-7. PubMed ID: 29510165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the effect of syringe surfaces on protein formulations.
    Majumdar S; Ford BM; Mar KD; Sullivan VJ; Ulrich RG; D'souza AJ
    J Pharm Sci; 2011 Jul; 100(7):2563-73. PubMed ID: 21319164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative Differentiation of Protein Aggregates From Other Subvisible Particles in Viscous Mixtures Through Holographic Characterization.
    Winters A; Cheong FC; Odete MA; Lumer J; Ruffner DB; Mishra KI; Grier DG; Philips LA
    J Pharm Sci; 2020 Aug; 109(8):2405-2412. PubMed ID: 32439328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.